Thomas M Zollner on OCEANIC-STROKE Study: Amazingly Good News for Patients With Stroke
Thomas M Zollner, Reproductive Health Cluster Lead at Bayer, reposted from Alexander Krupp on LinkedIn:
”Amazingly good news for patients with stroke: The Phase III study OCEANIC-STROKE in secondary stroke prevention met its primary endpoint.
Asundexian 50 mg once daily significantly reduced the risk of ischemic stroke compared to placebo, both in combination with antiplatelet therapy, in patients after a non-cardioembolic ischemic stroke or high-risk ischemic attack.
OCEANIC-STROKE is the first successfully completed Phase III study of a FactorXIa Inhibitor.
Each year, approximately 12 million people worldwide will experience a stroke.
Of these, 20-30% will be a recurrent stroke.
Despite available secondary stroke prevention options, the risk of secondary stroke remains high.
One in five stroke survivors will have another stroke within five years.”
Quoting Alexander Krupp‘s post:
”A new medicine was born today: We are just announcing positive results of the OCEANIC STROKE study in secondary stroke prevention.
There a few moments in a worklife when you can be part of a novel medicine being born.
For me, this is today: We are bringing a novel treatment option to millions of patients to reduce the risk of secondary ischemic stroke.
I am humble and honored to be part of such an incredible TeamBayer that has just made the impossible possible, unlocking superpowers in a new operating model DSO.
Thank you!”
Stay updated with Hemostasis Today.
-
Feb 23, 2026, 18:13Fight4Hematology Supports Research and Empowers the Next Generation – ASH
-
Feb 23, 2026, 17:59Wolfgang Miesbach: Real-World Evidence of Emicizumab on Joint Outcomes in Hemophilia A
-
Feb 23, 2026, 17:56Shiny K Kajal: The Transfusion Reaction We Often Miss
-
Feb 23, 2026, 17:53Radheshyam Meher: Contributing to the Transfusion Evidence Round-Up for International Childhood Cancer Day 2026
-
Feb 23, 2026, 17:46Mahesan Subramaniam: The Physiological Impact of Anger on Immunity
-
Feb 23, 2026, 17:42Bryan Fry: First Evidence That Bothrops atrox Venom Directly Activates Human Factor VII
-
Feb 23, 2026, 17:34Bastu Odoka: Why Blood Should NOT be Left at the Bedside to ‘Warm’
-
Feb 23, 2026, 17:28Henry Burkitt: Patients Are Challenging How the Medicines Policy System Works in England
-
Feb 23, 2026, 16:50Mutaz Al‑Sabah: Interesting Webinar on FH in Women is Now Available to Watch